Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus CARTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus CARTROL.
BETAPACE vs CARTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker